Monitor Nasdaq listing approval and IPO pricing relative to OTC market. The $4.00 offering price at a discount to the $5.00 OTC close suggests potential downward pressure post-IPO if the deal prices below market. Track Q3 2026 revenue trends for signs of stabilization after two years of sharp declines.
Executive Summary
Veri MedTech Holdings (VRHI) filed Amendment No. 7 to its S-1 IPO registration statement, maintaining the same core terms as prior amendments: a firm commitment offering of 3,750,000 shares at $4.00/share for gross proceeds of $15 million ($11.95M net). The company continues to experience declining revenue (~35% YoY in FY2025 to ~$10.8M, -28% in Q2 2026 to ~$2.0M), net losses, negative equity, and an auditor-identified going-concern risk that the IPO must resolve. The $4.00 offering price represents a ~20% discount to the recent OTC closing price of $5.00/share as of September 17, 2026, and the filing discloses substantial doubt about the company's ability to continue as a going concern without the IPO proceeds.
Key Financial Metrics
Key Facts
- Firm commitment IPO of 3,750,000 shares at $4.00/share for gross proceeds of $15 million ($11.95M net)
- Revenue declined ~35% YoY in FY2025 to ~$10.8M, and ~28% YoY in Q2 2026 to ~$2.0M
- Net loss of ~$2.32M in FY2025 and ~$496K in H1 2026
- Stockholders' deficit of ~$2.73M and working capital deficit of ~$2.46M as of June 30, 2026
- Auditor raised substantial doubt about going concern; IPO proceeds are critical for survival
- Offering price of $4.00 represents a ~20% discount to the recent OTC closing price of $5.00 as of September 17, 2026
- Company has applied for listing on Nasdaq Capital Market under symbol VRHI
- 1-for-2.5 reverse stock split effected on September 2, 2026
- Stock repurchase program authorized for up to 3,000,000 shares
- Series A Preferred Stock gives executives 80% voting control
Financial Impact
IPO of $15M gross ($11.95M net) is critical to address going-concern risk; revenue declining ~28-35% YoY with net losses continuing
Risk Factors
- Going-concern risk if IPO fails or is delayed
- Continued revenue decline (~28-35% YoY) driven by regulatory changes in key states like Florida
- Negative equity and working capital deficit of ~$2.7M and ~$2.5M respectively
- 80% voting control held by executives via Series A Preferred Stock, limiting minority shareholder influence
- Nasdaq listing not guaranteed; if denied, the offering will not consummate
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001096906-26-001390 |
| Document: vrhi_ex1z1.htm | 0001096906-26-001390 |
| Document: vrhi_ex10z6.htm | 0001096906-26-001390 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | S-1/A | $5.00 $4.41 | ▲ +11.80% | ▲ +12.49% | $4.41 (+11.80%) |
Sep 18, 2026 5w ago | S-1/A | $5.00 $4.41 | ▼ −11.80% | ▼ −10.89% | $4.41 (−11.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers